SCHEMBL4753320

SCHEMBL4753320

c1ccc(-c2ccccc2CN2CCN(c3ccccn3)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 5/20 0.65
DRD4 P21917 2/20 0.58
DRD2 P14416 1/20 0.58
DRD3 P35462 1/20 0.58
KMT2A Q03164 1/20 0.58
ALDH1A1 P00352 5/20 0.54
LMNA P02545 1/20 0.54
TSHR P16473 1/20 0.54
NPC1 O15118 1/20 0.53
MAPT P10636 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 1/20 0.53
POLB P06746 1/20 0.52
KCNH2 Q12809 1/20 0.52
KDM4E B2RXH2 2/20 0.52
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13681864 0.82 DRD2 (0.49) HTR7DRD4DRD2DRD3KMT2A
SCHEMBL12991804 0.82 ADORA1 (0.53) HTR7DRD4DRD2DRD3KMT2A
SCHEMBL28230641 0.82 HTR7 (0.80) HTR7DRD4DRD2DRD3
SCHEMBL13219071 0.80 ALDH1A1 (0.74) HTR7DRD4DRD2DRD3KMT2A
SCHEMBL27617560 0.80 KDM4E (0.60) DRD2KMT2AALDH1A1LMNAMAPT
SCHEMBL8111511 0.79 HTT (0.77) HTR7DRD4DRD2DRD3KMT2A
SCHEMBL15938148 0.79 HTR7 (1.00) HTR7DRD4DRD2DRD3KMT2A
SCHEMBL29764254 0.79 HTR7 (1.00) HTR7DRD4DRD2DRD3KMT2A
SCHEMBL13149646 0.78 HTR7 (0.55) HTR7ALDH1A1TSHRMAPTKDM4E
SCHEMBL4254056 0.78 DRD4 (0.56) DRD4DRD2DRD3KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008147864-A2 METHODS OF USING PIPERAZINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-12-04 WO claimed
WO-2008147864-A2 METHODS OF USING PIPERAZINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-12-04 WO disclosed